IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Merck & Co., Inc.

Q3 2025 Holdings

Filed 2025-11-12 | 13 holdings | $228.0M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Personalis Inc(PSNL)COM71535D106$91.6M14,044,94340.2%
Moderna Inc(MRNA)COM60770K107$59.6M2,308,19026.1%
Kymera Therapeutics Inc(KYMR)COM501575104$43.7M772,16519.2%
Alector Inc(ALEC)COM014442107$10.5M3,545,7194.6%
Entrada Therapeutics IncCOM29384C908$10.1M1,739,7684.4%
Evaxion Biotech A/SSPONSORED ADS29970R204$4.6M1,214,1262.0%
Sutro Biopharma IncCOM869367102$2.4M2,723,5091.0%
Viridian Therapeutics Inc(VRDN)COM92790C104$2.0M93,4140.9%
Lava Therapeutics NVSHSN51517105$1.8M1,149,3450.8%
Xilio Therapeutics Inc(XLO)COM98422T100$1.3M1,483,7580.5%
Carisma Therapeutics Inc(CARM)COM14216R101$403.7K1,473,2400.2%
Neuphoria Therapeutics Inc(NEUP)COM64136E102$118.2K10,0270.1%
Tuhura Biosciences(HURA)COM898920103$34.6K13,9500.0%